Jean Michel Cayuela Selected Research

Therapeutics

2/2014	Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
11/2012	Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean Michel Cayuela Research Topics

Disease

5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 02/2014 - 01/2007
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2021 - 01/2019
1	Philadelphia Chromosome 12/2021
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019
1	Drug Hypersensitivity Syndrome 05/2014
1	Pdgfra-Associated Chronic Eosinophilic Leukemia 09/2013
1	Blast Crisis (Blast Phase) 06/2011
1	T-Cell Lymphoma (Lymphoma, T Cell) 05/2008
1	Congenital Diaphragmatic Hernias 01/2005

Drug/Important Bio-Agent (IBA)

5	Imatinib Mesylate (Gleevec)FDA Link 02/2014 - 01/2007
3	Tyrosine Kinase InhibitorsIBA 02/2014 - 06/2011
1	asciminibIBA 12/2021
1	ponatinibIBA 12/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2019
1	Protein Tyrosine PhosphatasesIBA 01/2019
1	Interleukin-17 (Interleukin 17)IBA 05/2014
1	EpitopesIBA 05/2014
1	KIR ReceptorsIBA 11/2012
1	Dasatinib (BMS 354825)FDA Link 11/2012
1	Cytarabine (Cytosar-U)FDA LinkGeneric 06/2011
1	Daunorubicin (Cerubidine)FDA LinkGeneric 06/2011
1	Endothelin Receptors (Endothelin Receptor)IBA 01/2005

Therapy/Procedure

2	Therapeutics 02/2014 - 11/2012
1	Aftercare (After-Treatment) 05/2008